Trends in the Canadian and UK Biotech / Life Science Sector Dr. Patrik Frei December 2012 London
Venture Valuation Mission Independent assessment and valuation of technology driven companies / products in growth industries Life Sciences Database Biotechgate: www.biotechgate.com Offices Employees Clients HQ: Zurich with representative offices in North America, Europe and Asia (Seoul) 6 people in Switzerland, 8 representatives, JV in India Pharma, Biotech and Investors such as Novartis Venture Fund, GSK, European Investment Bank, 4SC, Arpida/Evolva, Celtic Pharma
Biotechgate Subscription based Database with 26 000 company profiles in over 70 countries 26 000 products 6 300 licensing opportunities 1 400 licensing deals Global Life Sciences Database to map clusters / countries 28 country databases Life Sciences statistics Membership / Regional Directory 3
Global Partners 4
Biotech numbers United Kingdom 624 Total Biotechnology Companies 629 172 Biotech - Therapeutics 154 399 Biotech R&D Services 206 53 Biotech - Other 269 91% Percentage of SME's 90% 7% Percentage of Companies Publicly Owned 14% USD 517 M Financing / Capital Raised in 2012 (Public and Private) USD 181 M 302 Licensing Opportunities 204
Geography United Kingdom
Companies Per Cluster: L-C and 200 Bi iotech Companies per Cluster 180 160 140 120 100 80 60 40 20 0 Cluster
Companies by Sector Biotechnology Companies in the U.K Breakdown on subcategory based on 1057 entries by 624 companies Bioinformatics and Bioelectronics 4% AgroBio 2% Therapeutics 16% Contract Research and Manufacturing 18% Other Services and Suppliers 26% Diagnostics and Analytical Services 22% Biotechnology Companies in Breakdown on subcategory based on 1018 entries by 629 companies Drug Delivery 5% AgroBio 9% Veterinary 5% Therapeutics 16% Contract Research & Manufacturing 11% Environment 13% Diagnostics and Analytical Services 13% Genomics and Proteomics 7% Other Services Food and and Suppliers Nutraceuticals 21% 7% Industrial Biotechnology 5%
Size of companies Size of Biotechnology Companies in the U.K (by number of employees) 1-10: 27% Size of Biotechnology Companies in (by number of employees) 201+ 15% 51-200: 22% 11-50: 36% 201+ 10% 51-200 20% 1-10: 20% 11-50: 50%
Ownership Public, Private and Subsidiary Companies in the U.K Public 6% Subsidiary 19% Private / independent 75% Public, Private and Subsidiary Companies in Subsidiary 10% Public 14% Private / independent 76%
Companies Founded 60 50 No. of Companies Founded 40 30 20 10 UK 0 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Year
Sources of Foundation Company Source of Foundation in the U.K Independent foundation 36% Undisclosed 28% Management buyout (MBO) 1% Other 3% Merger 1% Spin-off from company 2% Spin-off from public institution / NPO 2% Spin-off from university 11% Subsidiary 16% Company Source of Foundation in Independent foundation 48% Merger 1% Spin-off from company 1% Undisclosed 31% Other 3% Spin-off from public institution / NPO 1% Spin-off from university 5% Subsidiary 10%
Financing Biotech Therapeutic Financing Rounds 50 350 Number of Financing Rounds 45 40 35 30 25 20 15 300 250 200 150 100 Total Value in Million USD 10 5 50 0 2007 2008 2009 2010 2011 2012 Financing Value UK ($) 89 112 148 227 219 216 Financing Value ($) 53 84 5 52 83 56 No. of Rounds 4 11 5 5 8 6 No. of Rounds UK 12 12 15 17 19 16 0
Top 5 Financings 2012 Top 5 Largest Financings 2012 (Public/Private) USD Millions United Kingdom Circassia Ltd 76 81 YM Biosciences* Cell Medica 42 35 Thrasos Therapeutics PsiOxis Therapeutics 37 25 Resverlogix Corp* F2G Ltd 30 11 Zymeworks Inc ReNeuron Group Plc* 16 7 Lorus Therapeutics* * Denotes Public Company
Product pipeline Biotechnology Pipeline Preclinical Phase I Phase II Ph hase III UK UK UK UK 30 26 89 78 58 72 176 141 0 20 40 60 80 100 120 140 160 180 200 Number of Products
Product pipeline Pipeline Indications other Injury, poisoning and certain other consequences of external causes Diseases of the eye Diseases of the blood and blood-forming organs; immune disorders Mental and behavioural disorders Digestive system Skin and subcutaneous tissue Respiratory Genitourinary system Musculoskeletal system and connective tissue UK Diseases of the nervous system Infectious and parasitic diseases Cardiovascular Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified Neoplasms / cancer / oncology Endocrine, nutritional and metabolic diseases 0 20 40 60 80 100 120 140 160 Number of Products
Thank you for listening! Slides available on www.venturevaluation.com Tel.: +41 (43) 321 86 60 Venture Valuation AG Fax: +41 (43) 321 86 61 Kasernenstrasse 11 www.venturevaluation.com 8004 Zürich p.frei@venturevaluation.com Switzerland